Adiponectin and all-cause mortality in elderly people with type 2 diabetes

Diabetes Care

Volumn 35, Issue 9, 2012, Pages 1858-1863

  Singer, Jessica R ^a   Weinstock, Ruth ^d,e   Palmas, Walter ^a   Shea, Steven ^a,f   Teresi, Jeanne ^b,c   Luchsinger, José A ^a,f  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Research Division   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; SULFONYLUREA;

AGED; ARTICLE; DEATH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SEX;

ADIPONECTIN; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 84865492620     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2215     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008
2. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamicmodeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010;8:29
3. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
4. Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574
5. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585
6. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-1792
7. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin:more than just another fat cell hormone? Diabetes Care 2003;26:2442-2450
8. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009;302:179-188
9. Maiolino G, Cesari M, Sticchi D, et al. Plasma adiponectin for prediction of cardiovascular events and mortality in highrisk patients. J Clin Endocrinol Metab 2008;93:3333-3340
10. Dekker JM, Funahashi T, Nijpels G, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008;93:1489-1496
11. Menon V, Li L, Wang X, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2599-2606
12. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-1762
13. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease andmortality: the Rancho Bernardo study. Am J Epidemiol 2007;165:164-174
14. Poehls J, Wassel CL, Harris TB, et al.; Health ABC Study. Association of adiponectin with mortality in older adults: the Health, Aging, and Body Composition Study. Diabetologia 2009;52:591-595
15. Shea S, Starren J, Weinstock RS, et al. Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: rationale and design. J Am Med Inform Assoc 2002;9:49-62
16. Shea S, Weinstock RS, Starren J, et al. A randomized trial comparing telemedicine casemanagement with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus. J Am Med Inform Assoc 2006;13:40-51
17. Starren J, Hripcsak G, Sengupta S, et al. Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) project: technical implementation. J Am Med Inform Assoc 2002;9:25-36
18. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:200-206
19. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295
20. Lancaster GI, Febbraio MA. Adiponectin sphings into action. Nat Med 2011;17:37-38
21. Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011;17:55-63
22. Ouchi N, Walsh K. A novel role for adiponectin in the regulation of inflammation. Arterioscler Thromb Vasc Biol 2008;28:1219-1221
23. Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Diabetes Obes Metab 2007;9:282-289
24. Hara K, Horikoshi M, Yamauchi T, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006;29:1357-1362
25. Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakashima A, Kohno N. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab 2006;91:3873-3877
26. Zhu N, Pankow JS, Ballantyne CM, et al. High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. JClin Endocrinol Metab 2010;95:5097-5104
27. Almeda-Valdes P, Cuevas-Ramos D, Mehta R, et al. Total and high molecular weight adiponectin have similar utility for the identification of insulin resistance. Cardiovasc Diabetol 2010;9:26
28. Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006;114:623-629
29. Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004;68:975-981
30. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk ofmyocardial infarction in men. JAMA 2004;291:1730-1737
31. Krzyzanowska K, Aso Y, Mittermayer F, Inukai T, Brix J, Schernthaner G. High-molecular-weight adiponectin does not predict cardiovascular events in patients with type 2 diabetes. Transl Res 2009;153:199-203
32. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events amongmen with type 2 diabetes. Diabetes 2005;54:534-539
33. Sattar N, Nelson SM. Adiponectin, diabetes, and coronary heart disease in older persons: unraveling the paradox. J Clin Endocrinol Metab 2008;93:3299-3301
34. Teoh H, Strauss MH, Szmitko PE, Verma S. Adiponectin and myocardial infarction: A paradox or a paradigm? Eur Heart J 2006;27:2266-2268